A

Axsome Therapeutics

Biopharmaceutical company developing CNS disorder therapies

Director, Market Access Deal Analytics

Corporate Finance & FP&AConfirmed live in the last 24 hours
Full-timeNew York, NY, USA

About the Job

Requirements

  • A bachelor's degree in Economics, Statistics, Public Health, or a related field is required; an advanced degree (MBA, MPH, or PhD) is preferred.
  • At least 10 years of pharmaceutical or healthcare analytics experience focused on market access, pricing, or payer strategy.
  • A proven track record supporting product launches from an access analytics perspective.
  • Strong background in CNS therapeutic areas or other specialty or rare disease domains is highly preferred.
  • Ability to work on site Monday, Tuesday, and Thursday.
  • In-depth understanding of U.S. payer systems (commercial, Medicare, and Medicaid), reimbursement pathways, and formulary dynamics.
  • Proficiency with large-scale healthcare datasets, including claims, syndicated data sources, and longitudinal data sources.
  • Strong experience in payer contracting analytics, gross-to-net modeling, and assessing return on investment for market access investments.
  • Expertise in PBM and payer contract language.
  • Familiarity with data visualization platforms such as Power BI and Tableau, and cloud-based data ecosystems.
  • Ability to develop and validate predictive models using machine learning or regression-based techniques.
  • Experience managing external vendors, data partners, and cross-functional projects with multiple competing priorities.

Responsibilities

  • Conduct robust analytics to support business cases presented to the Pricing Terms Committee.
  • Support development of contracting language that meets business intent.
  • Lead analytics strategy to inform payer contracting, coverage optimization, and payer engagement across in-line and pipeline products.
  • Analyze claims data, including rejections, reversals, and abandonment, to understand coverage dynamics, formulary behavior, and implications for uptake and persistency.
  • Design modeling frameworks to guide formulary negotiations, segmentation strategies, and gross-to-net investment optimization.
  • Build predictive tools to estimate how payer policies and pricing dynamics influence new therapy adoption across CNS specialties.
  • Integrate payer analytics into National Account pull-through strategy, including actionable field-level insights for Market Access and Field Sales teams.
  • Support development of key metrics and report payer and PBM contract performance to the Pricing Committee and Executive Leadership.
  • Construct scenario-based forecasting models that simulate the impact of price and access changes on revenue and patient access.
  • Monitor formulary positions and their downstream impact on prescribing behavior, conversions, and persistency to inform contract renewal cycles.
  • Partner with Finance and gross-to-net teams to refine accruals based on evolving pricing and access dynamics.
  • Collaborate with Forecasting, Commercial Operations, HEOR, and Market Access Data Science teams to harmonize analytics across functions.
  • Embed analytics into pricing and access strategy development, ensuring recommendations are data-grounded and aligned with business goals.
  • Identify opportunities to improve data infrastructure, automate insight generation, and enhance decision support capabilities.

Desired Qualifications

  • An advanced degree (MBA, MPH, or PhD).
  • A strong background in CNS therapeutic areas or other specialty or rare disease domains.

About the Company

Axsome Therapeutics

Biopharmaceutical company developing CNS disorder therapies

Axsome Therapeutics develops therapies for central nervous system disorders. Its focus is on research, development, and commercialization of treatments for conditions such as major depressive disorder, treatment-resistant depression, Alzheimer's agitation, migraine, narcolepsy, fibromyalgia, and smoking cessation. The flagship product candidate, AXS-05, is an oral NMDA receptor antagonist intended to treat MDD and TRD; it works by blocking NMDA receptors to influence brain signaling involved in mood and depression, and has received FDA Breakthrough Therapy Designation. The company earns revenue from the commercialization of its drugs, partnerships, and potential licensing deals as its pipeline progresses through clinical trials and regulatory approvals. Axsome aims to provide effective CNS therapies, advance its drug pipeline, and improve patient outcomes and quality of life.

Company size
501-1,000
Company stage
IPO
Headquarters
New York City, New York
Founded
2012

Recently Posted Jobs

Explore more opportunities at Axsome Therapeutics

See more jobs